Drug recall · March 27, 2019
Docusate Sodium recall
Why: Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate Sodium 100mg softgel caps.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards, For institutional use only, Mfg by: Aenova Holding GmBh, Miami, Fl 33186, NDC 63739-0478-10
- Lots / codes
Lot # 0119397, Exp 02/2020
- Quantity
- 29,622 Blister Cards
- Company
- Rx Pak Division of McKesson Corporation, Memphis, TN
- Distribution
- Product was distributed to 5 major distributors who may have further distributed the product throughout the United States.
- Initiated
- January 16, 2019 · Voluntary: Firm initiated
- Classified
- March 15, 2019
- Reported
- March 27, 2019
- Ended
- December 2, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Docusate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.